Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 5:32 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 5:32 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zacks News
OPKO's BioReference Laboratories Offers COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
The Zacks Analyst Blog Highlights: Roche, Thermo Fisher Scientific, Becton, Dickinson and Teladoc Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Thermo Fisher Scientific, Becton, Dickinson and Teladoc Health
4 Potential Gainers Amid Intensifying Coronavirus Fears
by Trina Mukherjee
Amid the pandemonium associated with coronavirus, we look into four stocks that have the potential to benefit from this outbreak.
BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening
by Zacks Equity Research
BD (BDX) expects screening to ramp up by 1,000 per day once authorized.
BD MAX Gets CE Mark for Coronavirus Detection, Shares Up
by Zacks Equity Research
BD (BDX) and Spain's CerTest Biotec collaborate to detect the COVID-19 in Europe.
Coronavirus-Affected MedTech Drags S&P 500 Index Down
by Trina Mukherjee
Amid uncertainty surrounding the coronavirus outbreak, here are a few S&P 500 MedTech stocks that took a hit.
Becton Dickinson (BDX) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 MedTech Stocks to Rebound After Coronavirus-Led Recoil
by Sriparna Ghosal
As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.
PDCO or BDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. BDX: Which Stock Is the Better Value Option?
Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus
by Aparajita Dutta
The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
New Strong Sell Stocks for February 13th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.76% and 1.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
BD Life Sciences to Aid Becton, Dickinson (BDX) Q1 Earnings
by Zacks Equity Research
BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects fiscal 2020 revenue growth to be driven by recent product launches.
The Zacks Analyst Blog Highlights: Royal Dutch, TOTAL, Becton, Dickinson, Workday and TransDigm
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Royal Dutch, TOTAL, Becton, Dickinson, Workday and TransDigm
Top Research Reports for Royal Dutch Shell, TOTAL & Becton, Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Royal Dutch Shell (RDS.A), TOTAL (TOT) and Becton, Dickinson (BDX).
Becton Dickinson (BDX) Up 2.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects tariffs to impact its bottom line in first-quarter fiscal 2020.
BD's Onclarity HPV PMA Submission to Boost Women's Health
by Zacks Equity Research
Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.
Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.